DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
New York University Langone Medical Center
Nueva York, Estados UnidosPublications in collaboration with researchers from New York University Langone Medical Center (7)
2023
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299
2022
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
2021
-
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Vol. 17, Núm. 2, pp. 137-149
2020
-
Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
Journal of Clinical Oncology, Vol. 38, Núm. 23, pp. 2658-2666
-
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
European urology oncology, Vol. 3, Núm. 3, pp. 351-359
2017
-
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
The Lancet Oncology, Vol. 18, Núm. 11, pp. 1483-1492